All analyzed NU tissues showed unmethylated ST6GAL1 promoters; representative MSP results demonstrating an aberrant ST6GAL1 promoter region methylation status in bladder tumors are shown in Figure 4A. Overall, ST6GAL1 promoter methylation was detected in 32.9% (27/82) of bladder cancer samples. The gene discussed is ST6GAL1; the disease is urinary bladder cancer.